JP2022532356A5 - - Google Patents
Info
- Publication number
- JP2022532356A5 JP2022532356A5 JP2021567963A JP2021567963A JP2022532356A5 JP 2022532356 A5 JP2022532356 A5 JP 2022532356A5 JP 2021567963 A JP2021567963 A JP 2021567963A JP 2021567963 A JP2021567963 A JP 2021567963A JP 2022532356 A5 JP2022532356 A5 JP 2022532356A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- formulated
- hour
- administration
- infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025133004A JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗cd38抗体を投与して多発性骨髄腫を処置する方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847825P | 2019-05-14 | 2019-05-14 | |
| US62/847,825 | 2019-05-14 | ||
| US201962860739P | 2019-06-12 | 2019-06-12 | |
| US62/860,739 | 2019-06-12 | ||
| US201962899088P | 2019-09-11 | 2019-09-11 | |
| US62/899,088 | 2019-09-11 | ||
| EP20305223.8 | 2020-03-03 | ||
| EP20305223 | 2020-03-03 | ||
| PCT/US2020/032754 WO2020232173A1 (en) | 2019-05-14 | 2020-05-13 | Methods of administering anti-cd38 antibody to treat multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133004A Division JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗cd38抗体を投与して多発性骨髄腫を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532356A JP2022532356A (ja) | 2022-07-14 |
| JP2022532356A5 true JP2022532356A5 (cg-RX-API-DMAC7.html) | 2023-05-22 |
| JP7801132B2 JP7801132B2 (ja) | 2026-01-16 |
Family
ID=71094805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021567963A Active JP7801132B2 (ja) | 2019-05-14 | 2020-05-13 | 抗cd38抗体を投与して多発性骨髄腫を処置する方法 |
| JP2025133004A Pending JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗cd38抗体を投与して多発性骨髄腫を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133004A Pending JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗cd38抗体を投与して多発性骨髄腫を処置する方法 |
Country Status (15)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| MX2020007429A (es) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). |
| BR112021000065A2 (pt) * | 2018-07-10 | 2021-04-06 | Sanofi | Terapias de combinação contra câncer direcionando cd38 e tgf-beta |
| WO2020250033A1 (en) * | 2019-06-10 | 2020-12-17 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| IL302640A (en) * | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| KR20240024047A (ko) | 2021-04-08 | 2024-02-23 | 아티바 바이오테라퓨틱스, 인크. | Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| EP3313441B1 (en) * | 2015-06-24 | 2024-02-21 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| IL285110B2 (en) * | 2019-01-28 | 2025-11-01 | Sanofi Sa | Methods of treating multiple myeloma |
-
2020
- 2020-05-13 CN CN202510468038.XA patent/CN120501855A/zh active Pending
- 2020-05-13 MX MX2021013910A patent/MX2021013910A/es unknown
- 2020-05-13 JP JP2021567963A patent/JP7801132B2/ja active Active
- 2020-05-13 EP EP20733081.2A patent/EP3969004A1/en active Pending
- 2020-05-13 WO PCT/US2020/032754 patent/WO2020232173A1/en not_active Ceased
- 2020-05-13 MA MA055967A patent/MA55967A/fr unknown
- 2020-05-13 SG SG11202112513YA patent/SG11202112513YA/en unknown
- 2020-05-13 US US15/931,466 patent/US20210171650A1/en active Pending
- 2020-05-13 CN CN202080049892.8A patent/CN114080233A/zh active Pending
- 2020-05-13 CA CA3140034A patent/CA3140034A1/en active Pending
- 2020-05-13 BR BR112021022503A patent/BR112021022503A2/pt unknown
- 2020-05-13 KR KR1020217040398A patent/KR20220008305A/ko active Pending
- 2020-05-13 AU AU2020274169A patent/AU2020274169A1/en active Pending
- 2020-05-14 TW TW109116104A patent/TW202108624A/zh unknown
-
2021
- 2021-11-04 IL IL287832A patent/IL287832A/en unknown
- 2021-12-07 CO CONC2021/0016606A patent/CO2021016606A2/es unknown
-
2025
- 2025-08-08 JP JP2025133004A patent/JP2025166108A/ja active Pending